Central Nervous System Pharmacology — MCQs

Central Nervous System Pharmacology Indian Medical PG Practice Questions and MCQs

Question 121: Which statement is true regarding morphine?

A. Tolerance develops for all effects except miosis and constipation. (Correct Answer)
B. Tolerance to all effects develops with chronic usage.
C. Tolerance develops for all effects except euphoria and sedation.
D. Tolerance can develop to all effects in high doses.

Explanation: ### Explanation **1. Why Option A is Correct:** Morphine, a prototypical opioid agonist, exhibits a phenomenon where repeated administration leads to a diminished pharmacological response, requiring higher doses to achieve the same effect (**Tolerance**). However, tolerance does not develop uniformly across all organ systems. * **Tolerance develops rapidly** to effects like euphoria, sedation, analgesia, and respiratory depression. * **Minimal to no tolerance** develops for **miosis** (pinpoint pupils) and **constipation** (decreased GI motility). This is because the receptors responsible for these effects do not undergo significant downregulation or desensitization. **2. Why Other Options are Incorrect:** * **Option B & D:** These are incorrect because they suggest tolerance is universal. Even with chronic usage or extremely high doses, the constipating effect and pupillary constriction persist. This is why chronic opioid users almost always require stool softeners/laxatives. * **Option C:** This is incorrect because tolerance to euphoria and sedation develops quite rapidly, which often drives dose escalation in patients with opioid use disorder. **3. High-Yield Clinical Pearls for NEET-PG:** * **The "Mnemonic" for No Tolerance:** Remember **"Miosis and Constipation"** (or the "MC" of opioids). * **Triad of Opioid Poisoning:** Coma, Pinpoint pupils (Miosis), and Respiratory depression. * **Exception to Miosis:** **Meperidine (Pethidine)** is an opioid that causes *mydriasis* (dilation) instead of miosis due to its additional atropine-like (antimuscarinic) action. * **Lethal Effect:** Respiratory depression is the most common cause of death in acute opioid overdose; fortunately, tolerance *does* develop to this effect in chronic users, though it is never absolute.

Question 122: Which of the following is not an antiepileptic agent?

A. Phenytoin
B. Flunarizine (Correct Answer)
C. Topiramate
D. Carbamazepine

Explanation: **Explanation:** The correct answer is **Flunarizine**. While it is a pharmacological agent acting on the CNS, it is not classified as an antiepileptic drug (AED). **1. Why Flunarizine is the correct answer:** Flunarizine is a **non-selective calcium channel blocker** with additional dopamine D2 receptor blocking activity. Its primary clinical use is in the **prophylaxis of migraine** and the management of vertigo (vestibular disorders). Unlike AEDs, it does not stabilize neuronal membranes against high-frequency firing or enhance GABAergic inhibition to prevent seizures. **2. Why the other options are incorrect:** * **Phenytoin (Option A):** A classic first-generation AED. It works by blocking voltage-gated sodium channels in their inactive state, preventing the spread of seizure activity. * **Topiramate (Option C):** A broad-spectrum AED with multiple mechanisms: blocking sodium channels, enhancing GABA activity, and antagonizing AMPA/kainate glutamate receptors. It is used for both focal/generalized seizures and migraine prophylaxis. * **Carbamazepine (Option D):** An iminostilbene derivative and a first-line agent for focal seizures and trigeminal neuralgia. It works primarily by stabilizing inactivated sodium channels. **Clinical Pearls for NEET-PG:** * **Flunarizine Side Effects:** Can cause **extrapyramidal symptoms (EPS)** and depression due to its D2 blocking property; it is contraindicated in Parkinson’s disease. * **Drug of Choice (DOC):** * Trigeminal Neuralgia: Carbamazepine. * Absence Seizures: Ethosuximide (Valproate if generalized tonic-clonic seizures coexist). * Myoclonic Seizures: Valproate. * **Teratogenicity:** Phenytoin is associated with **Fetal Hydantoin Syndrome**, while Valproate is associated with **Neural Tube Defects**.

Question 123: Which of the following medications is used to maintain abstinence in alcohol dependence?

A. Naltrexone (Correct Answer)
B. Clonidine
C. Disulfiram
D. Naloxone

Explanation: **Explanation:** The management of alcohol dependence is divided into two phases: treatment of acute withdrawal and **maintenance of abstinence** (prevention of relapse). **Correct Option: A. Naltrexone** Naltrexone is an **opioid receptor antagonist** that is considered a first-line drug for maintaining abstinence. It works by blocking the $\mu$-opioid receptors, thereby reducing the "reward" or euphoria associated with alcohol consumption and significantly decreasing **craving**. Unlike disulfiram, it can be started while the patient is still drinking. **Incorrect Options:** * **B. Clonidine:** This is an $\alpha_2$-agonist used to manage the **autonomic hyperactivity** (tachycardia, hypertension) seen during *acute alcohol withdrawal*. It does not prevent relapse or maintain long-term abstinence. * **C. Disulfiram:** While used in alcohol dependence, it is an **aversion therapy** agent. It inhibits *aldehyde dehydrogenase*, causing a buildup of acetaldehyde if alcohol is consumed. However, recent clinical guidelines (and frequently NEET-PG patterns) prioritize Naltrexone and Acamprosate as superior for "maintaining abstinence" due to better compliance and reduced craving. * **D. Naloxone:** This is a short-acting opioid antagonist used intravenously for the emergency reversal of **acute opioid overdose**. It has no role in the long-term management of alcohol dependence due to its poor oral bioavailability and short half-life. **High-Yield Clinical Pearls for NEET-PG:** * **Acamprosate** (NMDA antagonist) is the other first-line drug for abstinence, especially useful in patients with liver disease (as Naltrexone is hepatotoxic). * **Disulfiram** does NOT reduce craving; it only acts as a psychological deterrent. * **Benzodiazepines** (e.g., Chlordiazepoxide) remain the "Gold Standard" for managing **acute withdrawal symptoms** and preventing seizures/delirium tremens.

Question 124: Which of the following adverse effects of levodopa is not minimized even after combining it with carbidopa?

A. Involuntary movements (Correct Answer)
B. Nausea and vomiting
C. Cardiac arrhythmia
D. 'On-off' effect

Explanation: ### Explanation To understand this question, we must differentiate between the **peripheral** and **central** effects of dopamine. Levodopa is a precursor that crosses the blood-brain barrier (BBB), while Carbidopa is a peripheral dopa-decarboxylase inhibitor that does **not** cross the BBB. **1. Why "Involuntary Movements" is the Correct Answer:** Carbidopa prevents the peripheral conversion of Levodopa to dopamine, ensuring more Levodopa reaches the brain. Once inside the brain, Levodopa is converted to dopamine to exert its therapeutic effect. **Involuntary movements (dyskinesias)** and **psychiatric symptoms** (hallucinations/psychosis) are mediated by high dopamine levels within the **Central Nervous System (CNS)**. Since Carbidopa increases the amount of dopamine available in the brain, it actually **exacerbates** or does not minimize these central side effects. **2. Analysis of Incorrect Options:** * **Nausea and Vomiting:** These are caused by dopamine stimulating the *Chemoreceptor Trigger Zone (CTZ)*, which lies outside the BBB. Carbidopa reduces peripheral dopamine, significantly minimizing these symptoms. * **Cardiac Arrhythmias:** These occur due to the action of peripheral dopamine on cardiac β-receptors. Carbidopa prevents peripheral dopamine formation, thus reducing cardiac side effects. * **'On-off' Effect:** While Carbidopa doesn't eliminate this entirely, it helps stabilize Levodopa levels. However, in the context of this classic pharmacological distinction, dyskinesia is the definitive "central" side effect that worsens with Carbidopa. **Clinical Pearls for NEET-PG:** * **The 1% Rule:** Without Carbidopa, only 1% of Levodopa reaches the brain. With Carbidopa, this increases significantly, allowing for a **75% reduction** in the required daily dose of Levodopa. * **Pyridoxine (Vitamin B6) Interaction:** B6 is a cofactor for dopa-decarboxylase. It increases peripheral metabolism of Levodopa, reducing its efficacy. This interaction is **abolished** when Carbidopa is added. * **Dominant Side Effect:** Dyskinesia (choreoathetosis) is the most common dose-limiting side effect of long-term Levodopa therapy.

Question 125: What is a known side effect of Levodopa?

A. Spasticity
B. Tremor
C. Akinesia
D. On-off phenomenon (Correct Answer)

Explanation: **Explanation:** **Levodopa** is the metabolic precursor of dopamine and remains the gold standard for managing Parkinson’s disease. The **"On-off phenomenon"** is a classic long-term complication of Levodopa therapy, typically occurring after 3–5 years of treatment. 1. **Why Option D is Correct:** The "On-off phenomenon" refers to sudden, unpredictable fluctuations in motor performance. The "On" period represents improved mobility (often accompanied by dyskinesias), while the "Off" period involves a sudden return of severe parkinsonian symptoms. This occurs due to the progressive loss of dopaminergic neurons, which reduces the brain's capacity to store dopamine, making the patient's clinical state entirely dependent on the fluctuating plasma levels of the drug. 2. **Why Other Options are Incorrect:** * **A. Spasticity:** This is a feature of Upper Motor Neuron (UMN) lesions. Parkinson’s is an extrapyramidal disorder characterized by **rigidity** (lead-pipe or cogwheel), not spasticity. * **B. Tremor:** Resting tremor is a primary symptom of Parkinson’s disease itself. Levodopa is used to *treat* tremors, not cause them. * **C. Akinesia:** Similar to tremor, akinesia (poverty of movement) is a cardinal symptom of the disease that Levodopa aims to alleviate. **High-Yield NEET-PG Pearls:** * **Peripheral Decarboxylase Inhibitors (Carbidopa/Benserazide):** Always co-administered with Levodopa to prevent peripheral conversion to dopamine, thereby reducing systemic side effects like nausea, vomiting, and cardiac arrhythmias. * **Vitamin B6 (Pyridoxine):** It is a cofactor for DOPA decarboxylase; taking it with Levodopa (without Carbidopa) enhances peripheral metabolism, reducing the drug's efficacy. * **Adverse Effects:** Early effects include GI distress and postural hypotension; late effects include dyskinesias and psychosis.

Question 126: What is the drug of choice for rapid cyclers in manic-depressive psychosis?

A. Carbamazepine
B. Valproate (Correct Answer)
C. Phenytoin
D. Lithium

Explanation: **Explanation:** **Valproate** is the drug of choice for **rapid cyclers** (defined as ≥4 episodes of mania or depression per year) and **mixed episodes** in Bipolar Affective Disorder (BPAD). While Lithium remains the gold standard for classic bipolar disorder, it is notably less effective in patients with rapid cycling patterns. Valproate’s superior efficacy in these cases is attributed to its multi-modal mechanism, including GABA enhancement and modulation of glutamate and sodium channels. **Analysis of Options:** * **Valproate (Correct):** Preferred for rapid cycling, mixed states, and patients who do not respond to Lithium. * **Lithium (Incorrect):** Though the first-line agent for typical mania and prophylaxis, it has a high failure rate in rapid cyclers. * **Carbamazepine (Incorrect):** Used as a second-line mood stabilizer or in refractory cases, but it is not the primary drug of choice for rapid cycling. It is also a potent enzyme inducer, complicating its side-effect profile. * **Phenytoin (Incorrect):** This is an anti-epileptic drug with no established role as a mood stabilizer in psychiatric practice. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Window:** Lithium has a narrow therapeutic index (0.8–1.2 mEq/L for acute mania; 0.5–0.8 mEq/L for maintenance). * **Teratogenicity:** Lithium causes **Ebstein’s Anomaly** (tricuspid valve defect), while Valproate is associated with **Neural Tube Defects** (Spina Bifida). * **Drug of Choice Summary:** * Classic Mania: Lithium * Rapid Cyclers/Mixed Mania: Valproate * Bipolar Depression: Quetiapine, Lurasidone, or Lamotrigine.

Question 127: Which of the following compounds acts as a benzodiazepine antagonist?

A. Flumazenil (Correct Answer)
B. Naloxone
C. Furazolidone
D. Naltrexone

Explanation: **Explanation:** **Correct Option: A. Flumazenil** Flumazenil is a specific **competitive antagonist** at the benzodiazepine (BZD) binding site on the **GABA-A receptor** complex [1], [2]. It blocks the actions of benzodiazepines and "Z-drugs" (Zolpidem, Zopiclone) but does not affect the actions of barbiturates or alcohol, as they bind to different sites [2], [3]. It is primarily used to reverse BZD-induced sedation for anesthesia or in the management of benzodiazepine overdose [2]. **Incorrect Options:** * **B. Naloxone:** This is a competitive **opioid antagonist** used for the emergency reversal of opioid overdose (e.g., morphine, heroin). It has no effect on GABA receptors. * **C. Furazolidone:** This is a nitrofuran derivative with **antibacterial and antiprotozoal** properties, commonly used for infectious diarrhea and giardiasis. It also possesses mild MAO-inhibitory activity. * **D. Naltrexone:** This is a long-acting **opioid antagonist**. While Naloxone is used for acute reversal, Naltrexone is used for the long-term maintenance of opioid-free states and to reduce cravings in alcohol dependence. **High-Yield Clinical Pearls for NEET-PG:** * **Half-life:** Flumazenil has a very short half-life (~1 hour). Because many benzodiazepines (like Diazepam) have longer half-lives, **re-sedation** can occur, requiring repeated doses or an infusion. * **Seizure Risk:** The most serious side effect of Flumazenil is the induction of **seizures**, especially in patients with long-term BZD dependence or those who have co-ingested tricyclic antidepressants (TCAs) [1]. * **Inverse Agonist:** Do not confuse Flumazenil (antagonist) with **Beta-carbolines**, which act as inverse agonists at the BZD site and can cause convulsions [1].

Question 128: All of the following are true about Clozapine except?

A. More potently blocks D2 as compared to D1 receptors.
B. Blood level below 350 ng/ml should be maintained to avoid agranulocytosis. (Correct Answer)
C. Should not be used along with Carbamazepine.
D. Should be discontinued if the WBC count is below 3,000/mm³ cells.

Explanation: **Explanation:** Clozapine is the prototype **Atypical Antipsychotic** (Second Generation). It is unique because it is the only drug proven effective for **treatment-resistant schizophrenia**. **1. Why Option B is the Correct Answer (The False Statement):** Agranulocytosis is an **idiosyncratic reaction**, meaning it is not dose-dependent or related to plasma drug levels. Maintaining a blood level below 350 ng/ml does not prevent agranulocytosis. In clinical practice, 350 ng/ml is actually often considered the *minimum* therapeutic threshold for efficacy, not a safety ceiling for bone marrow toxicity. **2. Analysis of Other Options:** * **Option A:** Clozapine has a unique receptor profile. Unlike typical antipsychotics, it has a **low affinity for D2 receptors** and a relatively higher affinity for D1, D4, and 5-HT2A receptors. This low D2 occupancy is why it rarely causes Extrapyramidal Side Effects (EPS). * **Option C:** Carbamazepine is a potent bone marrow suppressant. Combining it with Clozapine significantly increases the risk of **agranulocytosis**; therefore, concurrent use is contraindicated. * **Option D:** Strict hematological monitoring is mandatory. Clozapine must be interrupted if the **Total Leukocyte Count (TLC) falls below 3,000/mm³** or the Absolute Neutrophil Count (ANC) falls below 1,500/mm³. **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard:** For treatment-resistant schizophrenia (failed 2+ antipsychotics). * **Side Effects:** Sialorrhea (excessive salivation), weight gain, myocarditis, and lowering of seizure threshold (dose-dependent). * **Benefit:** Only antipsychotic proven to **reduce suicidal behavior** in schizophrenia. * **Metabolism:** Metabolized by **CYP1A2**; smoking induces this enzyme, leading to decreased Clozapine levels.

Question 129: Which of the following represents the mechanism of action of Memantine?

A. GABA antagonist
B. Alpha 2 antagonist
C. 5HT 2A antagonist
D. NMDA antagonist (Correct Answer)

Explanation: **Explanation:** **1. Why the Correct Answer is Right (NMDA Antagonist):** Memantine is a low-to-moderate affinity, non-competitive **NMDA (N-methyl-D-aspartate) receptor antagonist**. In Alzheimer’s disease, chronic overstimulation of NMDA receptors by glutamate leads to excessive calcium influx into neurons, causing "excitotoxicity" and neuronal death. Memantine blocks these receptors under conditions of excessive stimulation but allows for normal physiological signaling required for memory formation. It is specifically FDA-approved for **moderate-to-severe Alzheimer’s disease**. **2. Why the Incorrect Options are Wrong:** * **GABA antagonist (A):** GABA is the primary inhibitory neurotransmitter. Antagonizing it would lead to CNS excitation and seizures (e.g., Picrotoxin), which is the opposite of the desired effect in neurodegenerative management. * **Alpha 2 antagonist (B):** These drugs (e.g., Yohimbine, Mirtazapine) increase sympathetic outflow or serotonin/norepinephrine release. They are used in treating depression or erectile dysfunction, not dementia. * **5HT 2A antagonist (C):** This is the mechanism of atypical antipsychotics (e.g., Risperidone) and certain antidepressants (e.g., Trazodone). While used to manage behavioral symptoms in dementia, it is not the mechanism of Memantine. **3. Clinical Pearls for NEET-PG:** * **Combination Therapy:** Memantine is often combined with Donepezil (an AChE inhibitor) for synergistic effects in advanced Alzheimer's. * **Side Effects:** Generally well-tolerated; the most common side effects are **dizziness, headache, and confusion**. * **Excretion:** It is primarily excreted unchanged by the kidneys; dose adjustment is required in renal impairment. * **Key Distinction:** Unlike Donepezil (used for mild-to-moderate cases), Memantine is the drug of choice for **moderate-to-severe** Alzheimer's.

Question 130: Which of the following opioids is 100 times more potent than morphine?

A. Pethidine
B. Fentanyl (Correct Answer)
C. Pentazocine
D. Meperidine

Explanation: **Explanation:** **Correct Option: B (Fentanyl)** Fentanyl is a synthetic opioid agonist that acts primarily on the $\mu$ (mu) receptors. It is highly lipophilic, allowing it to cross the blood-brain barrier rapidly. In clinical practice, Fentanyl is approximately **100 times more potent than Morphine**. This high potency is due to its high affinity for the $\mu$-receptor and its rapid onset of action. It is commonly used in anesthesia (induction and maintenance) and for chronic pain management via transdermal patches. **Incorrect Options:** * **A & D (Pethidine/Meperidine):** These are the same drug. Pethidine is significantly **less potent** than morphine (roughly 1/10th the potency). It is unique because it has anticholinergic properties (causing tachycardia) and its metabolite, *normeperidine*, can cause seizures in patients with renal failure. * **C (Pentazocine):** This is an opioid agonist-antagonist ( $\kappa$-agonist and weak $\mu$-antagonist/partial agonist). It is much less potent than morphine and can precipitate withdrawal symptoms in opioid-dependent individuals. **High-Yield NEET-PG Pearls:** * **Potency Hierarchy:** Sufentanil (1000x) > Remifentanil/Fentanyl (100x) > Morphine (1x) > Pethidine (0.1x). * **Sufentanil** is the most potent opioid used clinically (500–1000 times more potent than morphine). * **Remifentanil** is notable for its ultra-short duration of action due to metabolism by plasma and tissue esterases. * **Miosis** is a classic sign of opioid overdose, but **Pethidine** is an exception (it may cause mydriasis due to its atropine-like action).

Practice by Chapter

General Anesthetics

Practice Questions

Local Anesthetics

Practice Questions

Sedative-Hypnotics

Practice Questions

Antiepileptic Drugs

Practice Questions

Antiparkinsonian Drugs

Practice Questions

Opioid Analgesics

Practice Questions

Drugs of Abuse and Addiction

Practice Questions

Psychostimulants

Practice Questions

Hallucinogens

Practice Questions

CNS Stimulants and Cognitive Enhancers

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free